Roquefort Therapeutics plc

LSE:ROQ Stock Report

Market Cap: UK£5.6m

Roquefort Therapeutics Valuation

Is ROQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ROQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ROQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ROQ's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ROQ?

Key metric: As ROQ is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ROQ. This is calculated by dividing ROQ's market cap by their current book value.
What is ROQ's PB Ratio?
PB Ratio1.1x
BookUK£4.93m
Market CapUK£5.55m

Price to Book Ratio vs Peers

How does ROQ's PB Ratio compare to its peers?

The above table shows the PB ratio for ROQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.3x
APTA Aptamer Group
7.4xn/aUK£6.5m
GENF Genflow Biosciences
7.1xn/aUK£6.1m
CIZ Cizzle Biotechnology Holdings
9.5xn/aUK£7.5m
VRCI Verici Dx
1xn/aUK£8.2m
ROQ Roquefort Therapeutics
1.1xn/aUK£5.6m

Price-To-Book vs Peers: ROQ is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (6.3x).


Price to Book Ratio vs Industry

How does ROQ's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.45m
VAL ValiRx
0.6xn/aUS$2.77m
No more companies available in this PB range
ROQ 1.1xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ROQ is good value based on its Price-To-Book Ratio (1.1x) compared to the UK Biotechs industry average (2.8x).


Price to Book Ratio vs Fair Ratio

What is ROQ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ROQ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ROQ's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies